Cargando…

Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose

BACKGROUND: The Plasmodium falciparum sexual-stage surface proteins Pfs25 and Pfs230 are antigen candidates for a malaria transmission-blocking vaccine (TBV), and have been widely investigated as such. It is not clear whether simultaneously presenting these two antigens in a particulate vaccine woul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Wei-Chiao, Deng, Bingbing, Mabrouk, Moustafa T., Seffouh, Amal, Ortega, Joaquin, Long, Carole, Miura, Kazutoyo, Wu, Yimin, Lovell, Jonathan F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453371/ https://www.ncbi.nlm.nih.gov/pubmed/32859199 http://dx.doi.org/10.1186/s12936-020-03368-5

Ejemplares similares

Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment
por: Huang, Wei-Chiao, et al.
Publicado: (2020)

The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2019)

Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages
por: Huang, Wei-Chiao, et al.
Publicado: (2022)

Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230
por: Miura, Kazutoyo, et al.
Publicado: (2022)

Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins
por: Singh, Kavita, et al.
Publicado: (2020)

Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice
por: Healy, Sara A., et al.
Publicado: (2021)

Identification of domains within Pfs230 that elicit transmission blocking antibody responses
por: Tachibana, Mayumi, et al.
Publicado: (2019)

Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission
por: Rausch, Kelly M., et al.
Publicado: (2023)

Development and Qualification of an Antigen Integrity Assay for a Plasmodium falciparum Malaria Transmission Blocking Vaccine Candidate, Pfs230
por: Miura, Kazutoyo, et al.
Publicado: (2022)

A human antibody epitope map of the malaria vaccine antigen Pfs25
por: Shukla, Niharika, et al.
Publicado: (2023)

Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine
por: Singh, Susheel K., et al.
Publicado: (2021)

Nanobodies against Pfs230 block Plasmodium falciparum transmission
por: Dietrich, Melanie H., et al.
Publicado: (2022)

N-Terminal Pfs230 Domain Produced in Baculovirus as a Biological Active Transmission-Blocking Vaccine Candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2017)

Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum
por: Singh, Susheel K., et al.
Publicado: (2019)

Rare Alleles and Signatures of Selection on the Immunodominant Domains of Pfs230 and Pfs48/45 in Malaria Parasites From Western Kenya
por: Ochwedo, Kevin O., et al.
Publicado: (2022)

The Dynamics of Naturally Acquired Immune Responses to Plasmodium falciparum Sexual Stage Antigens Pfs230 & Pfs48/45 in a Low Endemic Area in Tanzania
por: Bousema, Teun, et al.
Publicado: (2010)

Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230
por: Scaria, Puthupparampil V., et al.
Publicado: (2019)

TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25
por: Thompson, Elizabeth A., et al.
Publicado: (2018)

A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle
por: Salinas, Nichole D., et al.
Publicado: (2023)

Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer
por: Miura, Kazutoyo, et al.
Publicado: (2007)

Expression and purification optimization of an N-terminal Pfs230 transmission-blocking vaccine candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2019)

Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25
por: Scally, Stephen W., et al.
Publicado: (2017)

New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission
por: McGuire, Kathleen A., et al.
Publicado: (2017)

Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana
por: Acquah, Festus K., et al.
Publicado: (2017)

Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission
por: Kapoor, Neeraj, et al.
Publicado: (2018)

Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25
por: McLeod, Brandon, et al.
Publicado: (2019)

Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice
por: Brod, Florian, et al.
Publicado: (2018)

Profiling the Quality and Quantity of Naturally Induced Antibody Responses Against Pfs230 and Pfs48/45 Among Non-Febrile Children Living in Southern Ghana: A Longitudinal Study
por: Broni, Fermin K., et al.
Publicado: (2021)

Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
por: Wu, Yimin, et al.
Publicado: (2008)

Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45
por: Kundu, Prasun, et al.
Publicado: (2018)

Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates
por: Lee, Shwu-Maan, et al.
Publicado: (2016)

Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses
por: McLeod, Brandon, et al.
Publicado: (2022)

Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology
por: Li, Yuanyuan, et al.
Publicado: (2016)

Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies
por: Ko, Kuang-Ting, et al.
Publicado: (2022)

Algae-Produced Pfs25 Elicits Antibodies That Inhibit Malaria Transmission
por: Gregory, James A., et al.
Publicado: (2012)

Dynamics of anti-MSP3 and Pfs230 antibody responses and multiplicity of infection in asymptomatic children from southern Ghana
por: Amoah, Linda E., et al.
Publicado: (2018)

Poor CD4(+) T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans
por: Zaric, Marija, et al.
Publicado: (2021)

A Viral Vectored Prime-Boost Immunization Regime Targeting the Malaria Pfs25 Antigen Induces Transmission-Blocking Activity
por: Goodman, Anna L., et al.
Publicado: (2011)

Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody
por: Lennartz, Frank, et al.
Publicado: (2018)

Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230
por: Ivanochko, Danton, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t2j7p58o7r3jj0v4870drdm1va